Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(1):25-30
In May 2016 the U.S. Food and Drug Administration (FDA) approved changes to the labels of fluoroquinolone drugs for systemic use and advised to restrict their prescribing for the treatment of acute sinusitis, uncomplicated urinary tract infections and acute exacerbation of chronic bronchitis. This decision followed the recommendation of FDA Advisory Committees which concluded that the risk of rare serious and potentially permanent side effects of musculoskeletal, central and peripheral nervous system that can occur together in the same patient outweighed fluoroquinolones benefits in these infections. The article reviews data about fluoroquinolones and other antibiotics efficacy in acute sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections presented at FDA Advisory Committee meeting and published in available scientific literature.